PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY

Despite headwinds, the techbio sector continues to attract significant investment and drive innovation, exemplified by the 2024 launch of Xaira, backed by over $1 billion, aiming to design novel therapeutic proteins using advanced AI. The sector is maturing through strategic consolidation, significant capital deployment, technical diversification, and steady clinical validation, as illustrated by 25 techbio organizations, including notable players like Isomorphic Labs, Generate:Biomedicines, Recursion Pharmaceuticals, and Schrödinger Inc., all leveraging AI for drug discovery. Emerging players such as Archon Biosciences, AION Labs, and Antiverse are also making strides, while established companies like Insilico Medicine and Ginkgo Bioworks continue to expand their platforms and partnerships.

Authors from various departments and institutions contributed equally to the research.

UC San Francisco researchers developed customizable biological sensors, SNIPRs, that activate engineered cells only in tumor environments, potentially leading to more effective and less harmful cancer therapies.

13 participants, median age 15, received CAR-T cell therapy for DIPG/spinal cord diffuse midline glioma; 9 experienced benefits, including tumor volume reduction and improved neurologic function. Researchers determined lower CAR-T cell doses were safer. Drew, a participant, remains alive four years post-diagnosis, suggesting CAR-T therapy's potential. The study aims to refine the therapy for future patients.

BostonGene wins five 2024 Pharmaceutical Technology Excellence Awards for AI-driven innovations in cancer care, including Business Expansion, R&D, Innovation, Product Launches, and Marketing.

Nomic Bio Inc. and Parker Institute for Cancer Immunotherapy (PICI) collaborate to quantify circulating protein biomarkers associated with patient responses to immunotherapy. Using Nomic's nELISA platform, they will profile blood samples from PICI's RADIOHEAD cohort, aiming to elucidate immune cell communication pathways and treatment resistance, with data expected in early 2025.

BostonGene won five 2024 Pharmaceutical Excellence Awards: Business Expansion, R&D, Innovation, Product Launches, and Marketing. The company's AI-powered platform optimizes drug development and clinical trials, reduces pathology analysis variability, and predicts immunotherapy responses. BostonGene's global expansion and digital marketing strategy enhance personalized cancer care.

BostonGene won 5 Pharmaceutical Excellence Awards for Business Expansion, R&D, Innovation, Product Launches, and Marketing, recognizing its AI-powered platforms advancing cancer care. The company's AI-based digital pathology platform improves diagnostics, while its immune system profiling predicts immunotherapy response. BostonGene's global expansion and strategic marketing enhance personalized cancer treatment.

New data presented at SITC 39th Annual Meeting highlights ciforadenant's potential to overcome anti-PD1 resistance in mCRPC, identifying SPP1+ myeloid cells and adenosine signaling as key mechanisms.